Ballew Advisors’s Eli Lilly LLY Stock Holding History

Ballew Advisors’s Portfolio LLY Stock Details LLY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	–	Sell	-170	Closed	-$207K	–	139
2026 Q2	$207K	Buy	+170	New	+$174K	0.11%	123

Other funds holding LLY

Lilly Endowment Indiananapolis, Indiana $104B AUM 51.65% 1-Year Est. Return

PNC Financial Services Group Pittsburgh, Pennsylvania $191B AUM 30.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Fisher Asset Management Camas, Washington $348B AUM 26.9% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Amundi Paris, France $496B AUM 35.36% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return

Mitsubishi UFJ Asset Management Tokyo, Japan $194B AUM 32.2% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $174B AUM 33.96% 1-Year Est. Return

Ballew Advisors's LLY Position: Q3 2026 in Review

Ballew Advisors sold out of Eli Lilly (LLY) in Q3 2026, closing a stake of 170 shares — an estimated $207K sold.

Ballew Advisors first reported a position in LLY in Q2 2026 and held it in 1 quarter. The position peaked at $207K in Q2 2026. 2,976 funds tracked by Wall St. Rank hold LLY as of Q3 2026.

Ballew Advisors reported no remaining Eli Lilly position as of Q3 2026 after selling out during the quarter.
Ballew Advisors sold 170 Eli Lilly shares in Q3 2026, an estimated $207K.
Ballew Advisors first reported a position in Eli Lilly in Q2 2026 and held it in 1 quarter.
Ballew Advisors's Eli Lilly position peaked at $207K in Q2 2026.
2,976 funds tracked by Wall St. Rank held Eli Lilly as of Q3 2026.

Based on Ballew Advisors's 13F filing for Q3 2026, filed 5 Oct 2026.